Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to development of multiple products faster and more cost-effectively than the traditional biotech model... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NVDY | 16.71 | 0.19 | +1.15% |
| YieldMax NVDA Option Income Strategy ETF | |||
| QLC | 70.75 | 0.32 | +0.45% |
| FlexShares US Quality Large Cap ETF | |||
| PMARX | 12.43 | N/A | N/A |
| Victory Pioneer Equ Premium Income A | |||
| PMAPX | 21.88 | N/A | N/A |
| Principal MidCap S&P 400 Index R6 | |||
| GSRFX | 12.51 | N/A | N/A |
| Goldman Sachs Rising Dividend Gr R6 | |||
A.I.dvisor tells us that POLBF and NNVC have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that POLBF and NNVC's prices will move in lockstep.
| Ticker / NAME | Correlation To POLBF | 1D Price Change % | ||
|---|---|---|---|---|
| POLBF | 100% | N/A | ||
| NNVC - POLBF | 26% Poorly correlated | +13.82% | ||
| BOLT - POLBF | 26% Poorly correlated | -2.43% | ||
| BEIGF - POLBF | 25% Poorly correlated | N/A | ||
| DSGN - POLBF | 25% Poorly correlated | -6.54% | ||
| ALXO - POLBF | 22% Poorly correlated | -6.98% | ||
More | ||||